PFIZER INC Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
PFIZER INC (PFE) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$256.00 million for the 3-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-08-04
- PFIZER INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-06-28 was -$256.00M, a 108.87% decline year-over-year.
- PFIZER INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2026-03-29 was $2.70B, a 8.97% decline year-over-year.
- PFIZER INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-06-29 was $2.88B.
- PFIZER INC net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2025-03-30 was $2.97B.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month |
|---|---|---|
| 2026-06-28 | -$256.00M 10-Q · filed 2026-08-04 | $2.44B 10-Q · filed 2026-08-04 |
| 2026-03-29 | $2.70B 10-Q · filed 2026-05-05 | |
| 2025-06-29 | $2.88B 10-Q · filed 2026-08-04 | $5.85B 10-Q · filed 2026-08-04 |
| 2025-03-30 | $2.97B 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |